Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05827341
  4. Details
NCT05827341 Clinical Trial

A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

COVID-19 Clinical Trial

Official title:
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05827341
Other study ID # B2023-075-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2022
Est. completion date May 15, 2023

Study information
Verified date June 2023
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Recruitment information / eligibility
Status Completed
Enrollment 110
Est. completion date May 15, 2023
Est. primary completion date January 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: (1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available. Exclusion Criteria: - Patients who could not provide detailed information about COVID-19 infection.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• No intervention
No intervention needed

Locations
Country Name City State
China Department of Medical Oncology, Sun Yat-Sen University Cancer Center Guangzhou Guangdong

Sponsors (1)
Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary The severity of COVID-19 The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators 2 months
Primary Hospital admission rate of COVID-19 infection The percentage of malignant lymphoma patients who were admitted into hospital 2 months
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure